Hjem › Mavekreft › Michigan › Detroit
Kliniske studier for Mavekreft i Detroit, MI
16 studier for Mavekreft søker deltakere på steder i og rundt Detroit (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
RekruttererFrivillige helsepersonell ønskes velkommen
- Henry Ford Health Saint John Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
RekruttererFase 3
- Henry Ford Health, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- Henry Ford Cancer Institute, Detroit
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekruttererFase 1/2
- Brigitte Harris Cancer Pavilion BHCP, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekruttererFase 1/2
- Henry Ford Cancer Institute, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Investigative Site #120, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekruttererFase 1
- Karmanos Cancer Institute, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RekruttererFase 1
- Henry Ford Health System, Detroit
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
RekruttererFase 1
- Henry Ford Cancer-Detroit, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
Mavekreft-studier i andre byer
- Houston, TX42 studier
- Boston, MA32 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Baldwin Park, CA22 studier
- Los Angeles, CA22 studier
- Arlington, VA20 studier
- Dallas, TX19 studier
- San Antonio, TX19 studier
- St. Louis, MO18 studier
- Grand Rapids, MI18 studier
- Washington, DC16 studier
Andre studier i Detroit
- Ikke-småcellet lungekreft44 studier
- Brystkreft33 studier
- Kreft (alle typer)29 studier
- Kolorektal kreft26 studier
- Eggstokkreft26 studier
- Metastatisk kreft24 studier
- Prostatakreft22 studier
- Endometriekreft21 studier
- Lungekreft20 studier
- Multipelt myelom19 studier
- Plateepitelcancer i hode og hals15 studier
- Akut myelogen leukemi14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.